With variants spreading, Eli Lilly cuts solo COVID-19 antibody out of its U.S. supply deal

After lab testing found Eli Lilly's solo COVID-19 antibody couldn't match its combo against emerging coronavirus variants, the feds stopped using it in several states where one variant was running rampant.

Now, Lilly has stopped supplying bamlanivimab as a solo therapy to the U.S. completely. Under a revised supply deal with the government, Lilly's combo therapy—which pairs bamlanivimab with another new antibody, etesevimab—will be the only option on tap.